On August 15, 2024, Professor Ahmad Awada from Free University of Brussels in Belgium was invited by Cancer Center to visit the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU).
Ahmad Awada currently serves as the Head of CHIREC Cancer Center, Director of Oncology Department, Professor of Oncology Department from Free University of Brussels, Chairman of EORTC-IDMC, and an internationally-renowned expert in oncology. He has published multiple articles in international journals such as NJME, JCO and LANCET, established the Study Alliance of Breast Cancer Center, and led nearly 100 phase I/II/III clinical studies.
The heads of Medical Department, Cancer Center, Department of Breast Surgery, Department of Radiation Oncology and other departments of FAH attended the event. Relevant staff from breast cancer MDT consultation team participated in MDT consultation.
Ren Jie, Deputy Director of Medical Department, delivered a speech. Professor Ahmad Awada sincerely appreciated FAH for warm welcome. Subsequently, Professor Ahmad Awada gave a lecture entitled "Breast Cancer: best of ASCO 2024". He shared the findings of Rx PONDER clinical study that premenopausal women with low anti-Mullerian hormone (AMH) levels benefit less from postoperative adjuvant chemotherapy compared with those with moderate or high AMH levels. In addition, AMH is a more effective predictor for chemotherapy response than menopausal status, age and serum levels of other hormones related to ovarian function. Meantime, he also explicitly elucidated current treatment patterns and the latest research progress in drug selection strategy for hormone receptor-positive advanced breast cancer, and shared his viewpoints in combination with the latest research progress and clinical application of immunotherapy in breast cancer. Experts from various disciplines conducted in-depth discussions and exchanges with Professor Ahmad Awada on their respective specialties in combination with the latest research progress.
Subsequently, Physician Wang Fan from Oncology Department reported a complicated case of advanced triple-negative breast cancer with positive HRD and BRCA1 mutation. Professor Ahmad Awada illustrated the diagnosis and treatment process, selected treatment protocols post-progression and proposed targeted treatment plans and constructive suggestions based on the patient's clinical diagnosis and treatment characteristics. Experts attending MDT consultation had in-depth discussions with Professor Ahmad Awada regarding the pathological diagnosis, molecular typing conversion, genetic testing, immune therapy, targeted therapy, chemotherapy and ADC drugs, and the individualized selection of treatment protocols, and exchanged ideas regarding the differences in treatment scenarios and drug selection between Europe and China.
After the exchange activities, Professor Ahmad Awada visited Biobank, Precision Medicine Research Center and Research Center for Genetic and Cellular Therapy, respectively.
